Good news for developers of drugs for ultra-rare diseases – including cell and gene therapy firms – in the form of a new way of assessing them that’s being proposed by the US’s Food and Drug Administration (FDA). The regulator is looking at introducing what it calls a “plausible mechanism” pathway. This would allow approval of medicines for ultra-rare diseases, if there are very […]
Oncoinvent published Phase 1 study results for Radspherin® in ovarian cancer in Gynecologic Oncology Oncoinvent, a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers, announced the publication of 12-month data from its Phase 1 study of patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis. The results from the first patients have been […]
As anyone who has been following the weight loss wars knows, today’s treatments are far from perfect. They might be mega blockbusters, the likes of which have rarely been seen before in pharma, but that doesn’t mean they can’t be improved upon. They have to be injected – weekly. They often cause nausea. And they […]
Xeltis secures nearly €50m from the European Investment Bank (EIB) and existing shareholders to advance aXess, its vascular access conduit to the market Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, announces that it has secured nearly €50m of new financing, consisting of up to €37.5m […]
“Nothing for something” doesn’t sound like much of a deal. But when that “nothing” is zero tariffs on UK pharmaceutical products being sold in the US, then that’s something to shout about – in today’s world anyway. Topline details of the UK-US pharma deal were briefed earlier this week. In return for zero tariffs, the […]
